ZANTAC 300
LOE ApproachingNDAORALTABLET
Approved
Jun 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 300 is an oral tablet containing 300 mg of ranitidine, a histamine-2 receptor antagonist approved in 1983 for acid-related gastrointestinal disorders. The drug reduces gastric acid secretion by blocking H2 receptors on parietal cells. It is indicated for conditions such as peptic ulcer disease, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome.
LOE Approaching
As an aging product approaching loss of exclusivity with 30% competitive pressure, brand teams face portfolio transition planning and potential headcount reduction or redeployment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZANTAC 300 offers limited growth trajectory given its approaching loss of exclusivity and mature market status. Career value lies in mature product management, managed care negotiation, and defensive commercial strategy rather than growth-oriented roles.
Brand ManagerField Sales Representative
Worked on ZANTAC 300 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.